Pathogenic mutations in BRCA1 and BRCA2 are associated with high risks of breast and ovarian cancer. However, penetrance...
When the BRCA1 and BRCA2 tumour suppressor genes were identified in the early 1990s, the immediate implications of mappi...
Most women diagnosed with unilateral breast cancer without BRCA1 or BRCA2 mutations are at low risk of contralateral bre...
With the increasing request for BRCA1/BRCA2 mutation tests, several risk models have been developed to predict the prese...
...BRCA2 mutation carriers, respectively. The vast majority undergoes RRSO ≤40 (BRCA1) or ≤45 (BRCA2) years of age, provide...
...BRCA2, two in PALB2, and one in both BRCA2 and PALB2. There were 25 different mutations identified; of these, four mutat...
...BRCA2 formed nuclear foci after prolonged Cr(VI) exposure, while Rad51C foci formation was suppressed. These results sug...
...BRCA2 gene mutations. Existing, albeit limited, data indicate that risks of breast cancer are not increased with use of ...
...BRCA2, p53, ATM and PTEN), epigenetic transformation and involvement of estrogen receptors in development of breast canc...
...BRCA2-mutant serous ovarian adenocarcinoma, and PEO4, a reverted BRCA2-proficient line from the same patient after the d...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
